Loading...
XNASPLRX
Market cap825mUSD
Dec 27, Last price  
13.56USD
1D
-3.35%
1Q
19.89%
IPO
-41.95%
Name

Pliant Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:PLRX chart
P/E
—
P/S
522.26
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
28.89%
Rev. gr., 5y
%
Revenues
2m
-83.69%
0057,052,00041,817,0007,572,0009,685,0001,580,000
Net income
-161m
L+32.79%
-20,622,000-30,276,000185,000-39,745,000-17,907,000-121,498,000-161,336,000
CFO
-116m
L+22.96%
-16,924,000-28,328,000-2,750,000-37,271,000-75,443,000-94,631,000-116,361,000
Earnings
Feb 25, 2025

Profile

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
URL
https://pliantrx.com/
IPO date
Jun 03, 2020
Employees
155
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
1,580
-83.69%
9,685
27.91%
7,572
-81.89%
Cost of revenue
185,725
140,566
108,311
Unusual Expense (Income)
NOPBT
(184,145)
(130,881)
(100,739)
NOPBT Margin
Operating Taxes
(1,823)
(1,807)
Tax Rate
NOPAT
(184,145)
(129,058)
(98,932)
Net income
(161,336)
32.79%
(121,498)
578.49%
(17,907)
-54.95%
Dividends
Dividend yield
Proceeds from repurchase of equity
275,252
217,561
2,984
BB yield
-25.88%
-26.79%
-0.62%
Debt
Debt current
2,636
2,457
1,869
Long-term debt
11,372
19,244
12,519
Deferred revenue
Other long-term liabilities
Net debt
(480,237)
(309,486)
(186,208)
Cash flow
Cash from operating activities
(116,361)
(94,631)
(75,443)
CAPEX
(921)
(1,760)
(1,953)
Cash from investing activities
(127,012)
(150,204)
73,699
Cash from financing activities
274,405
226,854
2,527
FCF
(179,015)
(128,030)
(103,286)
Balance
Cash
494,245
331,187
200,596
Long term investments
Excess cash
494,166
330,703
200,217
Stockholders' equity
(499,397)
(340,365)
(215,289)
Invested Capital
985,663
669,522
421,542
ROIC
ROCE
EV
Common stock shares outstanding
58,719
42,016
35,846
Price
18.11
-6.31%
19.33
43.19%
13.50
-40.58%
Market cap
1,063,403
30.93%
812,168
67.83%
483,927
-40.09%
EV
583,166
502,682
297,719
EBITDA
(182,304)
(129,058)
(99,204)
EV/EBITDA
Interest
1,267
791
272
Interest/NOPBT